Anastrozole ( DrugBank: Anastrozole )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
78	下垂体前葉機能低下症	2
86	肺動脈性肺高血圧症	2
193	プラダー・ウィリ症候群	2

78. 下垂体前葉機能低下症

臨床試験数 : 494 / 薬物数 : 385 - (DrugBank : 49) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 100

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00133354 (ClinicalTrials.gov)	November 2001	19/8/2005	Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys	Double-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) Deficiency	Hypopituitarism	Drug: Arimidex (Anastrozole);Drug: Placebo;Drug: Growth Hormone	Nemours Children's Clinic	AstraZeneca;Genentech, Inc.;EMD Serono	Completed	11 Years	18 Years	Male	53	Phase 2/Phase 3	United States
2	EUCTR2012-001183-30-Outside-EU/EEA (EUCTR)		09/03/2012	The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay bone fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone.	Double-blind trial investigating the safety and efficacy of the inhibitor anastrozole (arimidex) in delaying epiphyseal fusion and increasing height potential of adolescent males with growth hormone (GH) deficiency.	hypopituitarism MedDRA version: 14.1;Level: PT;Classification code 10021067;Term: Hypopituitarism;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Arimidex Product Name: Arimidex Product Code: ZD1033 INN or Proposed INN: anastrozole Other descriptive name: ANASTROZOLE	Nemours Children's Clinic	NULL	NA			Female: no Male: yes	53		United States

86. 肺動脈性肺高血圧症

臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03229499 (ClinicalTrials.gov)	December 7, 2017	18/7/2017	Pulmonary Hypertension and Anastrozole Trial	Pulmonary Hypertension and Anastrozole Trial (PHANTOM)	Pulmonary Arterial Hypertension	Drug: Anastrozole;Drug: Placebo Oral Tablet	University of Pennsylvania	National Heart, Lung, and Blood Institute (NHLBI);Johns Hopkins University;University of Colorado, Denver;Rhode Island Hospital;Stanford University;Vanderbilt University;Washington University School of Medicine	Active, not recruiting	18 Years	N/A	All	84	Phase 2	United States
2	NCT01545336 (ClinicalTrials.gov)	October 2012	29/2/2012	Anastrozole in Patients With Pulmonary Arterial Hypertension	A Double-blind, Placebo-controlled Phase II Study of Anastrozole in Patients With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Anastrozole;Drug: Placebo	University of Pennsylvania	NULL	Completed	18 Years	N/A	All	18	Phase 2	United States

193. プラダー・ウィリ症候群

臨床試験数 : 111 / 薬物数 : 120 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1900027464	2019-12-01	2019-11-14	Efficacy and safety of anastrozole combined with growth hormone in the treatment of Prader Willi syndrome in boys of large bone age	Efficacy and safety of anastrozole combined with growth hormone in the treatment of Prader Willi syndrome in boys of large bone age	Prader-Willi syndrome	control group:Single rhGH therapy;observation group:Anastrazole combined with growth hormone therapy;	Children's Hospital of Zhejiang University School of Medicine	NULL	Pending			Male	control group:20;observation group:20;	Phase 4	China
2	NCT01520467 (ClinicalTrials.gov)	April 2012	25/1/2012	Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome	Efficacy and Tolerance of Treatment With an Aromatase Inhibitor (Anastrozole) to Limit the Progression of Bone Maturation Related to Pathological Adrenarche in Children With Silver-Russell or Prader-Willi Syndrome	Silver Russell Syndrome;Prader-Willi Syndrome	Drug: Anastrozole;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Active, not recruiting	5 Years	12 Years	Both	27	N/A	France

先頭へ